Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemoglobin glutamer-200 (bovine) is a veterinary pharmaceutical composed of glutaraldehyde-polymerized hemoglobin derived from bovine blood, forming large molecular aggregates ("glutamers") with a nominal molecular weight of 200 kDa[1][5]. It functions as a cell-free, acellular oxygen-carrying solution, classified as a hemoglobin-based oxygen carrier (HBOC)[1][3][5]. It is not a naturally occurring receptor, enzyme, transporter, or molecular target, but rather an exogenous product used mainly in emergency therapy for acute anemia and hemorrhagic shock, especially in canine medicine under the trade name Oxyglobin[5]. This product provides temporary oxygenation support when blood transfusions are not possible or available, with the hemoglobin component directly binding and releasing oxygen in plasma. Its elimination and pharmacokinetics depend on the polymer size distribution, with both smaller and larger aggregates cleared at different rates[1].\n\nNote: Hemoglobin glutamer-200 is not a molecular target in the sense of drug discovery (e.g., not a receptor, enzyme, etc.), but is itself a therapeutic product[5][3]. It is mainly licensed for veterinary use and is not approved for use in humans in the US or EU[5][7]. The molecule should not be confused with HBOC-201 (Hemopure), which is similar but a separate, trademarked hemoglobin-based oxygen carrier for potential human use[3].
Direct oxygen transport by glutaraldehyde-polymerized bovine hemoglobin in the plasma, bypassing the need for red blood cell transfusions[5][1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemoglobin glutamer-200 (bovine) (None established; sometimes abbreviated as HBOC-200 or Hemoglobin-based oxygen carrier-200 in the literature[1][5].).